Wegovy
Semaglutide specifically authorised for weight management in people who meet the clinical criteria.
Clinical comparison in English
Wegovy vs Mounjaro: which is better for weight loss?
We compare Wegovy, Mounjaro and Ozempic by active ingredient, authorised indication, frequency, follow-up and safety. The key is not choosing the “strongest” medicine, but identifying what is indicated and safe for you.
WegovySemaglutide
MounjaroTirzepatide
OzempicSemaglutideThey are not three versions of the same treatmentOzempic is authorised for type 2 diabetes; Wegovy and Mounjaro have weight-management indications under their product information.
Quick answer
Which is better for weight loss?
There is no universal answer. The decision depends on the indication, BMI and associated conditions, current medicines, risks and tolerance.
Mounjaro
Tirzepatide, with GIP and GLP-1 activity, authorised for weight management and type 2 diabetes under its product information.
Ozempic
Semaglutide authorised for type 2 diabetes. It should not be presented as an interchangeable general weight-loss treatment.
Direct comparison
Table: Wegovy vs Mounjaro vs Ozempic
| Treatment | Active ingredient | How it works | Relevant indication | Frequency | Prescription |
|---|---|---|---|---|---|
| WegovyWeight management | Semaglutide | GLP-1 receptor agonist | Authorised weight management when criteria are met | Weekly | Yes |
| MounjaroWeight and diabetes | Tirzepatide | Dual GIP/GLP-1 agonist | Weight management and type 2 diabetes | Weekly | Yes |
| OzempicType 2 diabetes | Semaglutide | GLP-1 receptor agonist | Not indicated for general weight loss; authorised for type 2 diabetes | Weekly | Yes |
Wegovy and Ozempic contain semaglutide, but they do not have the same indication and should not be interchanged without medical advice.
Each option
Differences that matter
Wegovy
Its indication is focused on weight management and the dose is increased gradually.
- Weekly administration
- Prescription and follow-up
- No guaranteed result
Mounjaro
It acts on GIP and GLP-1. The choice should not be based only on kilograms or percentages.
- Weekly administration
- Gradual dose escalation
- Individual assessment
Clinical decision
How treatment is chosen
A responsible comparison considers more than the average weight reported in one study.
Indication
BMI, associated conditions, diabetes and goals.
Safety
Medical history, medicines and contraindications.
Tolerance
Digestive effects and response to the dose.
Follow-up
Effectiveness, hydration, dosing and warning signs.
Dose and schedule
Appropriate escalation and previous experience.
Preferences
A shared decision after discussing alternatives.
Scientific data
Weight loss observed in studies
These charts summarise average results from two separate trials in adults with obesity or overweight without diabetes, alongside lifestyle intervention.
STEP 1 · semaglutide 2.4 mg
Wegovy · 1,961 participants · week 68SURMOUNT-1 · tirzepatide 15 mg
Mounjaro · 2,539 participants* · week 72Mean change from the beginning to the end of each study
The line connects only the baseline and published final result; it does not represent intermediate measurements.
STEP 1 · 68 weeksSURMOUNT-1 · 72 weeks
Important: this is not a direct comparison between medicines. The trials used different designs, durations and dosing schedules; SURMOUNT-1 studied several doses and the figure above is for 15 mg. Ozempic is not included because its authorised indication is type 2 diabetes, not general weight management.
How to interpret the results
An average percentage does not predict an individual result. Tolerated dose, adherence, nutrition, activity, associated conditions and follow-up all affect response.
Side effects and urgent care
Nausea, vomiting, diarrhoea, constipation and abdominal discomfort are common. Seek urgent care for severe and persistent abdominal pain, repeated vomiting with dehydration, breathing difficulty or an allergic reaction.
Online consultation🗓️ 🩺 ✉️
Book, speak with the doctor and receive a prescription if appropriate
Book
Choose a time.
Consult
Telephone or video.
Prescription
REMPe if appropriate.
Online consultation for €39. Medicine is not included; a prescription is not guaranteed.
Frequently asked questions
Questions about the comparison
Does Mounjaro produce more weight loss than Wegovy?
Average results from separate studies cannot always be compared directly. Indication, safety, tolerance and individual response matter.
Can Ozempic be used for weight loss?
Ozempic is authorised for type 2 diabetes and is not a general substitute for a medicine authorised for weight management.
Are Wegovy and Ozempic the same?
They share semaglutide, but have different indications and presentations.
Can I switch from Wegovy to Mounjaro?
Only after medical assessment of the previous dose, tolerance, indication and medical history.
Which causes fewer side effects?
Both can cause gastrointestinal effects; tolerance differs between people.
Do I need a prescription?
Yes. All three medicines are prescription only.
Does the consultation include the medicine?
No. The consultation costs €39 and the medicine is paid for separately at the pharmacy.
Which costs less?
It depends on the brand, presentation and dose. Confirm price and availability with an authorised pharmacy.
Loading secure booking…